Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9952937 | 0.81 | DDR1 (0.42) | POLBMAPTLMNASMN1; SMN2BACE1 | |
| SCHEMBL8100291 | 0.78 | KDM4E (0.36) | POLBBACE1SLC6A9KDM4EALDH1A1 | |
| SCHEMBL6928332 | 0.78 | MLYCD (0.43) | MAPTLMNAALDH1A1CYP1A1CYP1B1 | |
| SCHEMBL3033291 | 0.77 | CYP1A1 (0.46) | POLBMAPTLMNASMN1; SMN2BACE1 | |
| SCHEMBL16495054 | 0.77 | SLC6A2 (0.39) | POLBMAPTLMNAALDH1A1DDR1 | |
| SCHEMBL28230730 | 0.77 | ADRA2A (0.42) | POLBMAPTLMNAKDM4ECA1 | |
| SCHEMBL6853258 | 0.77 | POLB (0.42) | POLBMAPTLMNASMN1; SMN2BACE1 | |
| SCHEMBL362934 | 0.76 | ALDH1A1 (0.42) | MAPTKDM4EALDH1A1ADRA2AADRA2B | |
| SCHEMBL22867745 | 0.75 | ALDH1A1 (0.44) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL24576209 | 0.75 | RXFP1 (0.40) | MAPTSLC6A9KDM4ECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105849091-A | Method for preparing isoxaflutole | 安道麦阿甘有限公司 | 2016-08-10 | — | — | CN | disclosed |
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2010-07-01 | — | — | US | disclosed |
| CN-101123959-A | Aryl, heteroaryl and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions thereof for the treatment of human diseases | RENOVIS INC (US) | 2008-02-13 | — | — | CN | disclosed |
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1753714-A4 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS INC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1753714-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | Renovis, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1660011-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005079270-A2 | 2-SUBSTITUTED AND 4-SUBSTITUTED ARYL NITRONE COMPOUDS | RENOVIS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | RENOVIS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005016272-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-0524018-B1 | Isoxazole herbicides | RHONE POULENC AGRICULTURE (GB) | 2000-10-18 | — | — | EP | disclosed |
| CN-1039081-C | New herbicides | RHONE POULENC AGRICULTURE (GB) | 1998-07-15 | — | — | CN | disclosed |
| US-5424276-A | Herbicidal 4-acyl-5-pyridylisoxazoles | RHONE-POULENC AGRICULTURE LTD. (GB) | 1995-06-13 | — | — | US | disclosed |
| US-5366957-A | Plant growth regulators | RHONE-POULENC ARGRICULTURE LTD (GB) | 1994-11-22 | — | — | US | disclosed |
| EP-0524018-A1 | Isoxazole herbicides | RHONE-POULENC AGRICULTURE LTD. (GB) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | POLB 1809/4885MAPT 850/4885LMNA 2903/4885 |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | POLB 1809/4885MAPT 850/4885LMNA 2903/4885 |
| US-20100168112-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | POLB 1976/4885MAPT 4604/4885LMNA 3216/4885 |
| US-20050182060-A1 | 2-Substituted and 4-substituted aryl nitrone compounds | CXCR2, CCL5, CCL2 | POLB 1976/4885MAPT 4604/4885LMNA 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.